Request for Covid-19 Impact Assessment of this Report
Rise in incidence of various cancer conditions, aging population, westernized diet, shift to sedentary lifestyle, and surge in tobacco smoke exposure due to urbanization in China are the key factors that drive the growth of the cancer. This in turn boosts the growth of the China oncology drugs market. Furthermore, rise in cancer awareness and increase in availability of cancer drugs are expected to boost the market growth. However, the use of traditional Chinese medicine (TCM) to cure cancer and high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drugs therapies are expected to restrain the growth of the market. Conversely, high potential of emerging economies and increase in number of pipeline products are expected to provide new opportunities for market players in future.
The China oncology drugs market is segmented based on drug class type and indication. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. By indication, it is categorized into blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, lung cancer, skin cancer, ovarian cancer, cervical cancer, kidney cancer, and other cancers.
KEY MARKET BENEFITS
• This report entails a detailed quantitative analysis along with the current China oncology drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
• The market forecast is studied from 2019 to 2026.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
Key market segments
By Drug Class Type
• Chemotherapy
• Targeted Therapy
• Immunotherapy Therapy
• Hormonal Therapy
By Indication
• Blood Cancer
• Breast Cancer
• Gastrointestinal Cancer
• Prostate Cancer
• Lung Cancer
• Skin Cancer
• Ovarian Cancer
• Cervical Cancer
• Kidney Cancer
• Other Cancers
LIST of KEY PLAYERS PRofILED IN THE REPORT
• AbbVie Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Celgene Corporation
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Shanghai Junshi Biosciences Co., Ltd.
• Beigene
• Jiangsu Hengrui Medicine Co., Ltd
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.3.1. List of Key Players Profiled In The Report
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies, 2018
3.3. Porter’S Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Industrial Collaboration
3.4.1.2. In House Manufacturing
3.4.1.3. Increase In Incidences of Cancers In The Chinese Population
3.4.2. Restraint
3.4.2.1. Preference of Generics And Biosimilars
3.4.3. Opportunity
3.4.3.1. Increase In Number of Pipeline Drugs
3.4.4. Impact Analyses
Chapter 4: China Oncology Drugs Market, By Drug Class Type
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Chemotherapy
4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast
4.3. Targeted Therapy
4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast
4.4. Immunotherapy (Biologic Therapy)
4.4.1. Key Market Trends, Growth Factors, And Opportunities
4.4.2. Market Size And Forecast
4.5. Hormonal Therapy
4.5.1. Key Market Trends, Growth Factors, And Opportunities
4.5.2. Market Size And Forecast
Chapter 5: China Oncology Drugs Market, By Indication
5.1. Overview
5.1.1. Cancer Incidences In China, 2018
5.1.2. Market Size And Forecast
5.2. Blood Cancer
5.2.1. Market Size And Forecast
5.3. Breast Cancer
5.3.1. Market Size And Forecast
5.4. Gastrointestinal And Urinary Cancer
5.4.1. Market Size And Forecast
5.4.2. Gb/Cholangiocarcinoma
5.4.2.1. Market Size And Forecast
5.4.3. Bladder Cancer
5.4.3.1. Market Size And Forecast
5.4.4. Pancreatic Cancer
5.4.4.1. Market Size And Forecast
5.5. Prostate Cancer
5.5.1. Market Size And Forecast
5.6. Lung Cancer
5.6.1. Market Size And Forecast
5.6.2. Small Cell Lung Cancer (Sclc)
5.6.2.1. Market Size And Forecast
5.7. Skin Cancer
5.7.1. Market Size And Forecast
5.8. Ovarian Cancer
5.8.1. Market Size And Forecast
5.9. Cervical Cancer
5.9.1. Market Size And Forecast
5.10. Kidney Cancer
5.10.1. Market Size And Forecast,
5.11. Other Cancers
5.11.1. Market Size And Forecast
Chapter 6: Company Profiles
6.1. Abbvie Inc.
6.1.1. Company Overview
6.1.2. Company Snapshot
6.1.3. Operating Business Segments
6.1.4. Product Portfolio
6.1.5. Business Performance
6.2. Astellas Pharma Inc.
6.2.1. Company Overview
6.2.2. Company Snapshot
6.2.3. Operating Business Segments
6.2.4. Product Portfolio
6.2.5. Business Performance
6.3. Astrazeneca Plc
6.3.1. Company Overview
6.3.2. Company Snapshot
6.3.3. Operating Business Segments
6.3.4. Product Portfolio
6.3.5. Business Performance
6.4. Bristol-Myers Squibb Company
6.4.1. Company Overview
6.4.2. Company Snapshot
6.4.3. Operating Business Segments
6.4.4. Product Portfolio
6.4.5. Business Performance
6.4.6. Key Strategic Moves And Developments
6.5. Celgene Corporation
6.5.1. Company Overview
6.5.2. Company Snapshot
6.5.3. Operating Business Segments
6.5.4. Product Portfolio
6.5.5. Business Performance
6.5.6. Key Strategic Moves And Developments
6.6. F. Hoffmann-La Roche Ltd.
6.6.1. Company Overview
6.6.2. Company Snapshot
6.6.3. Operating Business Segments
6.6.4. Product Portfolio
6.6.5. Business Performance
6.6.6. Key Strategic Moves And Developments
6.7. Johnson & Johnson
6.7.1. Company Overview
6.7.2. Company Snapshot
6.7.3. Operating Business Segments
6.7.4. Product Portfolio
6.7.5. Business Performance
6.7.6. Key Strategic Moves And Developments
6.8. Shanghai Junshi Biosciences Co., Ltd.
6.8.1. Company Overview
6.8.2. Company Snapshot
6.8.3. Operating Business Segments
6.8.4. Product Portfolio
6.8.5. Business Performance
6.8.6. Key Strategic Moves And Developments
6.9. Beigene
6.9.1. Company Overview
6.9.2. Company Snapshot
6.9.3. Operating Business Segments
6.9.4. Product Portfolio
6.9.5. Business Performance
6.9.6. Key Strategic Moves And Developments
6.10. Jiangsu Hengrui Medicine Co., Ltd.
6.10.1. Company Overview
6.10.2. Company Snapshot
6.10.3. Operating Business Segments
6.10.4. Product Portfolio
6.10.5. Key Strategic Moves And Developments
Table 01. China Oncology Drugs Market, By Drug Class Type, 2018-2026 ($Million)
Table 02. China Oncology Drugs Market, List of Chemotherapy Drugs
Table 03. China Oncology Drugs Market, List of Targeted Therapy Drugs
Table 04. China Oncology Drugs Market, List of Immunotherapeutic Drugs
Table 05. China Oncology Drugs Market, List of Hormonal Therapy Drugs
Table 06. China Oncology Drugs Market, By Indication, 2018–2026 ($Million)
Table 07. Abbvie: Company Snapshot
Table 08. Abbvie: Operating Segments
Table 09. Abbvie: Product Portfolio
Table 10. Astellas: Company Snapshot
Table 11. Astellas: Products And Services
Table 12. Astellas: Product Portfolio
Table 13. Astrazeneca: Company Snapshot
Table 14. Astrazeneca: Operating Segments
Table 15. Astrazeneca: Product Portfolio
Table 16. Bristol-Myers Squibb: Company Snapshot
Table 17. Bristol-Myers Squibb: Product Portfolio
Table 18. Celgene: Company Snapshot
Table 19. Celgene: Operating Segments
Table 20. Celgene: Product Type Portfolio
Table 21. Roche: Company Snapshot
Table 22. Roche: Operating Segments
Table 23. Roche: Product Type Portfolio
Table 24. J&J: Company Snapshot
Table 25. J&J: Operating Segments
Table 26. J&J: Product Type Portfolio
Table 27. Shanghai Junshi Biosciences Co., Ltd.: Company Snapshot
Table 28. Shanghai Junshi Biosciences Co., Ltd: Operating Segments
Table 29. Shanghai Junshi Biosciences Co., Ltd.: Product Type Portfolio
Table 30. Beigene: Company Snapshot
Table 31. Beigene: Operating Segments
Table 32. Beigene: Product Type Portfolio
Table 33. Jiangsu Hengrui Medicine Co., Ltd: Company Snapshot
Table 34. Jiangsu Hengrui Medicine Co., Ltd: Operating Segments
Table 35. Jiangsu Hengrui Medicine Co., Ltd: Product Type Portfolio
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...